Increases in human papillomavirus vaccine coverage over 12 months among a community-recruited cohort of gay, bisexual, and other men who have sex with men in Canada
Starting in 2015/16, most Canadian provinces introduced publicly-funded human papillomavirus (HPV) vaccination programs for gay, bisexual, and other men who have sex with men (GBM) aged ≤ 26 years. We estimated 12-month changes in HPV vaccine coverage among community-recruited GBM from 2017 to 2021...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2022-06, Vol.40 (26), p.3690-3700 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3700 |
|---|---|
| container_issue | 26 |
| container_start_page | 3690 |
| container_title | Vaccine |
| container_volume | 40 |
| creator | Chambers, Catharine Deeks, Shelley L. Sutradhar, Rinku Cox, Joseph de Pokomandy, Alexandra Grennan, Troy Hart, Trevor A. Lambert, Gilles Moore, David M. Coutlée, François Grace, Daniel Grewal, Ramandip Jollimore, Jody Lachowsky, Nathan Nisenbaum, Rosane Ogilvie, Gina Sauvageau, Chantal Tan, Darrell H.S. Burchell, Ann N. |
| description | Starting in 2015/16, most Canadian provinces introduced publicly-funded human papillomavirus (HPV) vaccination programs for gay, bisexual, and other men who have sex with men (GBM) aged ≤ 26 years. We estimated 12-month changes in HPV vaccine coverage among community-recruited GBM from 2017 to 2021 and identified baseline factors associated with vaccine initiation (≥1 dose) or series completion (3 doses) among participants who were unvaccinated or partially vaccinated at baseline.
We recruited sexually-active GBM aged ≥ 16 years in Montreal, Toronto, and Vancouver, Canada, from 02/2017 to 08/2019 and followed them over a median of 12 months (interquartile range = 12–13 months). We calculated the proportion who initiated vaccination (≥1 dose) or completed the series (3 doses) by 12-month follow-up. Analyses were stratified by city and age-eligibility for the publicly-funded programs at baseline (≤26 years or > 26 years). We used multivariable logistic regression to identify baseline factors associated with self-reported incident vaccine initiation or series completion.
Among 165 unvaccinated participants aged ≤ 26 years at baseline, incident vaccine initiation (≥1 dose) during follow-up was 24.1% in Montreal, 33.3% in Toronto, and 38.9% in Vancouver. Among 1,059 unvaccinated participants aged > 26 years, incident vaccine initiation was 3.4%, 8.9%, and 10.9%, respectively. Higher education and trying to access pre-exposure prophylaxis for HIV were associated with incident vaccination among those aged ≤ 26 years, while younger age, residing in Vancouver (vs. Montreal), being diagnosed with anogenital warts, having both government and private extended medical insurance, and being vaccinated against influenza were associated with incident vaccination among those aged > 26 years.
We observed substantial gains in HPV vaccine coverage among young GBM within 5 + years of targeted program implementation, but gaps remain, particularly among older men who are ineligible for publicly-funded programs. Findings suggest the need for expanded public funding or insurance coverage for HPV vaccines. |
| doi_str_mv | 10.1016/j.vaccine.2022.05.019 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2665561153</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X22005904</els_id><sourcerecordid>2665561153</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-16685d0f184f61bb4f2283cdc69e2180ec5ead16f3342df9643c031ba0ede4593</originalsourceid><addsrcrecordid>eNqFkU2O1DAQhS0EYpqBI4AssWExCf6J3ckKjVr8jDQSG5DYWY5d6biV2I2dZOjbsJmLzMlw0w0LNqxKqvrqVek9hF5SUlJC5dtduWhjnIeSEcZKIkpCm0doRes1L5ig9WO0IkxWRUXJtwv0LKUdIURw2jxFF1yI9VpyvkL3N95E0AkSdh7386g93uu9G4Yw6sXFOeHzHWzCAlFvAR8rpuzh5xj81Cesc91inYFxnL2bDkUEE2c3gc29PsQJhw5v9eEKty7Bj1kPV1h7i8PUZ6URPL7rA-71AjiP8Z2b-t_d_NFGe231c_Sk00OCF-d6ib5-eP9l86m4_fzxZnN9Wxje8KmgUtbCko7WVSdp21YdYzU31sgGGK0JGAHaUtlxXjHbNbLihnDaagIWKtHwS_TmpLuP4fsMaVKjSwaGQXsIc1JMSiEkpYJn9PU_6C7M0efvMrUmZM0EkZkSJ8rEkFKETu2jG3U8KErUMUe1U2d_1TFHRYTKOea9V2f1uR3B_t36E1wG3p0AyHYsDqJKxoE3YF02f1I2uP-c-AUsnbO5</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2670072506</pqid></control><display><type>article</type><title>Increases in human papillomavirus vaccine coverage over 12 months among a community-recruited cohort of gay, bisexual, and other men who have sex with men in Canada</title><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Chambers, Catharine ; Deeks, Shelley L. ; Sutradhar, Rinku ; Cox, Joseph ; de Pokomandy, Alexandra ; Grennan, Troy ; Hart, Trevor A. ; Lambert, Gilles ; Moore, David M. ; Coutlée, François ; Grace, Daniel ; Grewal, Ramandip ; Jollimore, Jody ; Lachowsky, Nathan ; Nisenbaum, Rosane ; Ogilvie, Gina ; Sauvageau, Chantal ; Tan, Darrell H.S. ; Burchell, Ann N.</creator><creatorcontrib>Chambers, Catharine ; Deeks, Shelley L. ; Sutradhar, Rinku ; Cox, Joseph ; de Pokomandy, Alexandra ; Grennan, Troy ; Hart, Trevor A. ; Lambert, Gilles ; Moore, David M. ; Coutlée, François ; Grace, Daniel ; Grewal, Ramandip ; Jollimore, Jody ; Lachowsky, Nathan ; Nisenbaum, Rosane ; Ogilvie, Gina ; Sauvageau, Chantal ; Tan, Darrell H.S. ; Burchell, Ann N.</creatorcontrib><description>Starting in 2015/16, most Canadian provinces introduced publicly-funded human papillomavirus (HPV) vaccination programs for gay, bisexual, and other men who have sex with men (GBM) aged ≤ 26 years. We estimated 12-month changes in HPV vaccine coverage among community-recruited GBM from 2017 to 2021 and identified baseline factors associated with vaccine initiation (≥1 dose) or series completion (3 doses) among participants who were unvaccinated or partially vaccinated at baseline.
We recruited sexually-active GBM aged ≥ 16 years in Montreal, Toronto, and Vancouver, Canada, from 02/2017 to 08/2019 and followed them over a median of 12 months (interquartile range = 12–13 months). We calculated the proportion who initiated vaccination (≥1 dose) or completed the series (3 doses) by 12-month follow-up. Analyses were stratified by city and age-eligibility for the publicly-funded programs at baseline (≤26 years or > 26 years). We used multivariable logistic regression to identify baseline factors associated with self-reported incident vaccine initiation or series completion.
Among 165 unvaccinated participants aged ≤ 26 years at baseline, incident vaccine initiation (≥1 dose) during follow-up was 24.1% in Montreal, 33.3% in Toronto, and 38.9% in Vancouver. Among 1,059 unvaccinated participants aged > 26 years, incident vaccine initiation was 3.4%, 8.9%, and 10.9%, respectively. Higher education and trying to access pre-exposure prophylaxis for HIV were associated with incident vaccination among those aged ≤ 26 years, while younger age, residing in Vancouver (vs. Montreal), being diagnosed with anogenital warts, having both government and private extended medical insurance, and being vaccinated against influenza were associated with incident vaccination among those aged > 26 years.
We observed substantial gains in HPV vaccine coverage among young GBM within 5 + years of targeted program implementation, but gaps remain, particularly among older men who are ineligible for publicly-funded programs. Findings suggest the need for expanded public funding or insurance coverage for HPV vaccines.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2022.05.019</identifier><identifier>PMID: 35577633</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Age ; Anogenital ; Bisexuality ; Coronaviruses ; COVID-19 vaccines ; Disease transmission ; Education ; Gender identity ; Hepatitis ; HIV ; Human immunodeficiency virus ; Human Papillomavirus ; Human Papillomavirus Vaccine ; Immunization ; Infections ; Influenza ; Insurance ; Insurance coverage ; Males ; Men ; Men Who Have Sex with Men ; Pandemics ; Primary Prevention ; Prophylaxis ; Public health ; Sexually transmitted diseases ; STD ; Vaccination ; Vaccines ; Warts</subject><ispartof>Vaccine, 2022-06, Vol.40 (26), p.3690-3700</ispartof><rights>2022</rights><rights>Copyright © 2022. Published by Elsevier Ltd.</rights><rights>Copyright Elsevier Limited Jun 9, 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-16685d0f184f61bb4f2283cdc69e2180ec5ead16f3342df9643c031ba0ede4593</citedby><cites>FETCH-LOGICAL-c393t-16685d0f184f61bb4f2283cdc69e2180ec5ead16f3342df9643c031ba0ede4593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2670072506?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35577633$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chambers, Catharine</creatorcontrib><creatorcontrib>Deeks, Shelley L.</creatorcontrib><creatorcontrib>Sutradhar, Rinku</creatorcontrib><creatorcontrib>Cox, Joseph</creatorcontrib><creatorcontrib>de Pokomandy, Alexandra</creatorcontrib><creatorcontrib>Grennan, Troy</creatorcontrib><creatorcontrib>Hart, Trevor A.</creatorcontrib><creatorcontrib>Lambert, Gilles</creatorcontrib><creatorcontrib>Moore, David M.</creatorcontrib><creatorcontrib>Coutlée, François</creatorcontrib><creatorcontrib>Grace, Daniel</creatorcontrib><creatorcontrib>Grewal, Ramandip</creatorcontrib><creatorcontrib>Jollimore, Jody</creatorcontrib><creatorcontrib>Lachowsky, Nathan</creatorcontrib><creatorcontrib>Nisenbaum, Rosane</creatorcontrib><creatorcontrib>Ogilvie, Gina</creatorcontrib><creatorcontrib>Sauvageau, Chantal</creatorcontrib><creatorcontrib>Tan, Darrell H.S.</creatorcontrib><creatorcontrib>Burchell, Ann N.</creatorcontrib><title>Increases in human papillomavirus vaccine coverage over 12 months among a community-recruited cohort of gay, bisexual, and other men who have sex with men in Canada</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Starting in 2015/16, most Canadian provinces introduced publicly-funded human papillomavirus (HPV) vaccination programs for gay, bisexual, and other men who have sex with men (GBM) aged ≤ 26 years. We estimated 12-month changes in HPV vaccine coverage among community-recruited GBM from 2017 to 2021 and identified baseline factors associated with vaccine initiation (≥1 dose) or series completion (3 doses) among participants who were unvaccinated or partially vaccinated at baseline.
We recruited sexually-active GBM aged ≥ 16 years in Montreal, Toronto, and Vancouver, Canada, from 02/2017 to 08/2019 and followed them over a median of 12 months (interquartile range = 12–13 months). We calculated the proportion who initiated vaccination (≥1 dose) or completed the series (3 doses) by 12-month follow-up. Analyses were stratified by city and age-eligibility for the publicly-funded programs at baseline (≤26 years or > 26 years). We used multivariable logistic regression to identify baseline factors associated with self-reported incident vaccine initiation or series completion.
Among 165 unvaccinated participants aged ≤ 26 years at baseline, incident vaccine initiation (≥1 dose) during follow-up was 24.1% in Montreal, 33.3% in Toronto, and 38.9% in Vancouver. Among 1,059 unvaccinated participants aged > 26 years, incident vaccine initiation was 3.4%, 8.9%, and 10.9%, respectively. Higher education and trying to access pre-exposure prophylaxis for HIV were associated with incident vaccination among those aged ≤ 26 years, while younger age, residing in Vancouver (vs. Montreal), being diagnosed with anogenital warts, having both government and private extended medical insurance, and being vaccinated against influenza were associated with incident vaccination among those aged > 26 years.
We observed substantial gains in HPV vaccine coverage among young GBM within 5 + years of targeted program implementation, but gaps remain, particularly among older men who are ineligible for publicly-funded programs. Findings suggest the need for expanded public funding or insurance coverage for HPV vaccines.</description><subject>Age</subject><subject>Anogenital</subject><subject>Bisexuality</subject><subject>Coronaviruses</subject><subject>COVID-19 vaccines</subject><subject>Disease transmission</subject><subject>Education</subject><subject>Gender identity</subject><subject>Hepatitis</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Human Papillomavirus</subject><subject>Human Papillomavirus Vaccine</subject><subject>Immunization</subject><subject>Infections</subject><subject>Influenza</subject><subject>Insurance</subject><subject>Insurance coverage</subject><subject>Males</subject><subject>Men</subject><subject>Men Who Have Sex with Men</subject><subject>Pandemics</subject><subject>Primary Prevention</subject><subject>Prophylaxis</subject><subject>Public health</subject><subject>Sexually transmitted diseases</subject><subject>STD</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Warts</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkU2O1DAQhS0EYpqBI4AssWExCf6J3ckKjVr8jDQSG5DYWY5d6biV2I2dZOjbsJmLzMlw0w0LNqxKqvrqVek9hF5SUlJC5dtduWhjnIeSEcZKIkpCm0doRes1L5ig9WO0IkxWRUXJtwv0LKUdIURw2jxFF1yI9VpyvkL3N95E0AkSdh7386g93uu9G4Yw6sXFOeHzHWzCAlFvAR8rpuzh5xj81Cesc91inYFxnL2bDkUEE2c3gc29PsQJhw5v9eEKty7Bj1kPV1h7i8PUZ6URPL7rA-71AjiP8Z2b-t_d_NFGe231c_Sk00OCF-d6ib5-eP9l86m4_fzxZnN9Wxje8KmgUtbCko7WVSdp21YdYzU31sgGGK0JGAHaUtlxXjHbNbLihnDaagIWKtHwS_TmpLuP4fsMaVKjSwaGQXsIc1JMSiEkpYJn9PU_6C7M0efvMrUmZM0EkZkSJ8rEkFKETu2jG3U8KErUMUe1U2d_1TFHRYTKOea9V2f1uR3B_t36E1wG3p0AyHYsDqJKxoE3YF02f1I2uP-c-AUsnbO5</recordid><startdate>20220609</startdate><enddate>20220609</enddate><creator>Chambers, Catharine</creator><creator>Deeks, Shelley L.</creator><creator>Sutradhar, Rinku</creator><creator>Cox, Joseph</creator><creator>de Pokomandy, Alexandra</creator><creator>Grennan, Troy</creator><creator>Hart, Trevor A.</creator><creator>Lambert, Gilles</creator><creator>Moore, David M.</creator><creator>Coutlée, François</creator><creator>Grace, Daniel</creator><creator>Grewal, Ramandip</creator><creator>Jollimore, Jody</creator><creator>Lachowsky, Nathan</creator><creator>Nisenbaum, Rosane</creator><creator>Ogilvie, Gina</creator><creator>Sauvageau, Chantal</creator><creator>Tan, Darrell H.S.</creator><creator>Burchell, Ann N.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20220609</creationdate><title>Increases in human papillomavirus vaccine coverage over 12 months among a community-recruited cohort of gay, bisexual, and other men who have sex with men in Canada</title><author>Chambers, Catharine ; Deeks, Shelley L. ; Sutradhar, Rinku ; Cox, Joseph ; de Pokomandy, Alexandra ; Grennan, Troy ; Hart, Trevor A. ; Lambert, Gilles ; Moore, David M. ; Coutlée, François ; Grace, Daniel ; Grewal, Ramandip ; Jollimore, Jody ; Lachowsky, Nathan ; Nisenbaum, Rosane ; Ogilvie, Gina ; Sauvageau, Chantal ; Tan, Darrell H.S. ; Burchell, Ann N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-16685d0f184f61bb4f2283cdc69e2180ec5ead16f3342df9643c031ba0ede4593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Age</topic><topic>Anogenital</topic><topic>Bisexuality</topic><topic>Coronaviruses</topic><topic>COVID-19 vaccines</topic><topic>Disease transmission</topic><topic>Education</topic><topic>Gender identity</topic><topic>Hepatitis</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Human Papillomavirus</topic><topic>Human Papillomavirus Vaccine</topic><topic>Immunization</topic><topic>Infections</topic><topic>Influenza</topic><topic>Insurance</topic><topic>Insurance coverage</topic><topic>Males</topic><topic>Men</topic><topic>Men Who Have Sex with Men</topic><topic>Pandemics</topic><topic>Primary Prevention</topic><topic>Prophylaxis</topic><topic>Public health</topic><topic>Sexually transmitted diseases</topic><topic>STD</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Warts</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chambers, Catharine</creatorcontrib><creatorcontrib>Deeks, Shelley L.</creatorcontrib><creatorcontrib>Sutradhar, Rinku</creatorcontrib><creatorcontrib>Cox, Joseph</creatorcontrib><creatorcontrib>de Pokomandy, Alexandra</creatorcontrib><creatorcontrib>Grennan, Troy</creatorcontrib><creatorcontrib>Hart, Trevor A.</creatorcontrib><creatorcontrib>Lambert, Gilles</creatorcontrib><creatorcontrib>Moore, David M.</creatorcontrib><creatorcontrib>Coutlée, François</creatorcontrib><creatorcontrib>Grace, Daniel</creatorcontrib><creatorcontrib>Grewal, Ramandip</creatorcontrib><creatorcontrib>Jollimore, Jody</creatorcontrib><creatorcontrib>Lachowsky, Nathan</creatorcontrib><creatorcontrib>Nisenbaum, Rosane</creatorcontrib><creatorcontrib>Ogilvie, Gina</creatorcontrib><creatorcontrib>Sauvageau, Chantal</creatorcontrib><creatorcontrib>Tan, Darrell H.S.</creatorcontrib><creatorcontrib>Burchell, Ann N.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chambers, Catharine</au><au>Deeks, Shelley L.</au><au>Sutradhar, Rinku</au><au>Cox, Joseph</au><au>de Pokomandy, Alexandra</au><au>Grennan, Troy</au><au>Hart, Trevor A.</au><au>Lambert, Gilles</au><au>Moore, David M.</au><au>Coutlée, François</au><au>Grace, Daniel</au><au>Grewal, Ramandip</au><au>Jollimore, Jody</au><au>Lachowsky, Nathan</au><au>Nisenbaum, Rosane</au><au>Ogilvie, Gina</au><au>Sauvageau, Chantal</au><au>Tan, Darrell H.S.</au><au>Burchell, Ann N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increases in human papillomavirus vaccine coverage over 12 months among a community-recruited cohort of gay, bisexual, and other men who have sex with men in Canada</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2022-06-09</date><risdate>2022</risdate><volume>40</volume><issue>26</issue><spage>3690</spage><epage>3700</epage><pages>3690-3700</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Starting in 2015/16, most Canadian provinces introduced publicly-funded human papillomavirus (HPV) vaccination programs for gay, bisexual, and other men who have sex with men (GBM) aged ≤ 26 years. We estimated 12-month changes in HPV vaccine coverage among community-recruited GBM from 2017 to 2021 and identified baseline factors associated with vaccine initiation (≥1 dose) or series completion (3 doses) among participants who were unvaccinated or partially vaccinated at baseline.
We recruited sexually-active GBM aged ≥ 16 years in Montreal, Toronto, and Vancouver, Canada, from 02/2017 to 08/2019 and followed them over a median of 12 months (interquartile range = 12–13 months). We calculated the proportion who initiated vaccination (≥1 dose) or completed the series (3 doses) by 12-month follow-up. Analyses were stratified by city and age-eligibility for the publicly-funded programs at baseline (≤26 years or > 26 years). We used multivariable logistic regression to identify baseline factors associated with self-reported incident vaccine initiation or series completion.
Among 165 unvaccinated participants aged ≤ 26 years at baseline, incident vaccine initiation (≥1 dose) during follow-up was 24.1% in Montreal, 33.3% in Toronto, and 38.9% in Vancouver. Among 1,059 unvaccinated participants aged > 26 years, incident vaccine initiation was 3.4%, 8.9%, and 10.9%, respectively. Higher education and trying to access pre-exposure prophylaxis for HIV were associated with incident vaccination among those aged ≤ 26 years, while younger age, residing in Vancouver (vs. Montreal), being diagnosed with anogenital warts, having both government and private extended medical insurance, and being vaccinated against influenza were associated with incident vaccination among those aged > 26 years.
We observed substantial gains in HPV vaccine coverage among young GBM within 5 + years of targeted program implementation, but gaps remain, particularly among older men who are ineligible for publicly-funded programs. Findings suggest the need for expanded public funding or insurance coverage for HPV vaccines.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>35577633</pmid><doi>10.1016/j.vaccine.2022.05.019</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2022-06, Vol.40 (26), p.3690-3700 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2665561153 |
| source | Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland |
| subjects | Age Anogenital Bisexuality Coronaviruses COVID-19 vaccines Disease transmission Education Gender identity Hepatitis HIV Human immunodeficiency virus Human Papillomavirus Human Papillomavirus Vaccine Immunization Infections Influenza Insurance Insurance coverage Males Men Men Who Have Sex with Men Pandemics Primary Prevention Prophylaxis Public health Sexually transmitted diseases STD Vaccination Vaccines Warts |
| title | Increases in human papillomavirus vaccine coverage over 12 months among a community-recruited cohort of gay, bisexual, and other men who have sex with men in Canada |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T10%3A44%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increases%20in%20human%20papillomavirus%20vaccine%20coverage%20over%2012%C2%A0months%20among%20a%20community-recruited%20cohort%20of%20gay,%20bisexual,%20and%20other%20men%20who%20have%20sex%20with%20men%20in%20Canada&rft.jtitle=Vaccine&rft.au=Chambers,%20Catharine&rft.date=2022-06-09&rft.volume=40&rft.issue=26&rft.spage=3690&rft.epage=3700&rft.pages=3690-3700&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2022.05.019&rft_dat=%3Cproquest_cross%3E2665561153%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2670072506&rft_id=info:pmid/35577633&rft_els_id=S0264410X22005904&rfr_iscdi=true |